摘要
2019新型冠状病毒肺炎(新冠肺炎)的高发病率和危重患者的高病死率给全球公共卫生提出了巨大挑战,鉴于目前抗病毒药物、疫苗等有效药物的临床验证和开发尚需要时间,恢复期血浆(CP)再次引起了临床医师的关注。本文对CP在新冠肺炎成人患者治疗中的应用进展进行了综述,阐述了CP治疗可能的作用机制、CP治疗新冠肺炎患者的循证依据、CP临床应用的安全性、影响CP临床效果的主要因素等方面,以期为临床医师选择CP治疗新冠肺炎成人患者提供一定依据。
The high incidence of coronavirus disease 2019(COVID-19)and high mortality of critical patients have posed a great challenge to global public health resources.Currently there are no specific antiviral drugs and vaccines available for COVID-19,which has drawn the attention to the usefulness of convalescent plasma(CP)again,so the application of CP in the adult patients with COVID-19 is reviewed.The main contents include the possible mechanism of CP,the evidence of CP in the treatment of COVID-19 patients,the safety of clinical application of CP and the main factors affecting the clinical effect of CP,which may provide some basis for clinicians to choose CP for the treatment of adult patients with COVID-19.
作者
李双玲
赵鸿
孙月明
王鹏
李海霞
段美丽
Li Shuangling;Zhao Hong;Sun Yueming;Wang Peng;Li Haixia;Duan Meili(Department of Critical Care Medicine,Peking University First Hospital,Beijing 100034,China;Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China;Department of Blood Transfusion,Peking University First Hospital,Beijing 100034,China;Department of Laboratory,Peking University First Hospital,Beijing 100034,China;Department of Critical Care Medicine,Peking Friendship Hospital,Beijing 100050,China)
出处
《中华危重病急救医学》
CAS
CSCD
北大核心
2020年第6期646-651,共6页
Chinese Critical Care Medicine
基金
国家重点研发计划新型冠状病毒感染的肺炎疫情应急项目(2020YFC0844100)。
